Partnership plans trial of antidote to Factor Xa inhibitors

02/6/2013 | American City Business Journals

Portola Pharmaceuticals has entered a partnership with Bayer HealthCare and Johnson & Johnson's Janssen Pharmaceuticals to support a midstage clinical trial of PRT-4445, a reversal agent for anticoagulant Factor Xa inhibitor drugs. The study will involve patients treated with rivaroxaban.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD